.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Therapeutic proteins, including monoclonal antibodies, have transformed the management of chronic and life-threatening illnesses. However, manufacturing these complex biomolecules requires cell-based expression systems that naturally generate thousands of contaminants. Host cell protein impurities represent one of the most significant challenges for drug developers and clinicians today. These process-related proteins can compromise drug stability and significantly increase the risk of immunogenicity in patients. Consequently, the biotechnology industry and global regulators prioritize the precise tracking and removal of these impurities to ensure therapeutic efficacy and patient safety.
Recent progress in process analytics has introduced highly sensitive workflows for identifying contaminants. While traditional ELISA methods provide a total count of impurities, they often lack the specificity needed to identify individual high-risk proteins. In contrast, liquid chromatography-mass spectrometry (LC-MS) now allows for the detailed identification and quantification of specific host cell protein impurities. Specifically, the United States Pharmacopeia recently introduced General Chapter <1132.1> to standardize these mass spectrometry techniques. This shift helps manufacturers detect problematic enzymes, such as proteases or lipases, which can degrade the therapeutic product and reduce its shelf life.
Advancements in both upstream and downstream processing have significantly enhanced the clearance of contaminants. Nonconventional removal technologies now supplement traditional chromatography to achieve higher purity levels. Furthermore, researchers are using innovative computational tools to predict the immunogenicity of host cell protein impurities based on their amino acid sequences. These tools enable manufacturers to optimize their processes early in development, reducing the likelihood of adverse immune responses during clinical trials. Therefore, integrating advanced analytics and robust purification designs is essential for maintaining the high standards required for modern biopharmaceuticals.
Host cell proteins are process-related impurities produced by the host organism, such as CHO cells or E. coli, during the manufacture of recombinant therapeutic proteins.
Residual impurities can act as adjuvants or foreign antigens, triggering unwanted immune responses. Additionally, certain host cell enzymes can degrade the drug product, leading to reduced potency or the formation of harmful aggregates.
Manufacturers traditionally use ELISA to measure total impurity levels. However, they are increasingly adopting LC-MS as an orthogonal method to identify and quantify specific high-risk proteins that ELISA might miss.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional biopharmaceutical consultancy. Refer to the latest local and national guidelines for clinical practice.
References
Alhuthali S et al. Host cell protein impurities in therapeutic proteins: overview of advances in detection, nonconventional removal technologies and immunogenicity assessment. J Biol Eng. 2026 May 19. doi: 10.1186/s13036-026-00685-2. PMID: 42157068.
United States Pharmacopeia. General Chapter <1132.1> Residual Host Cell Protein Measurement in Biopharmaceuticals by Mass Spectrometry. 2024.
Central Drugs Standard Control Organisation (CDSCO). Guidance on Similar Biologics: Regulatory Requirements for Marketing Authorization in India. 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
An overview of recent advances in the detection and removal of host cell protein impurities to improve the safety and efficacy of therapeutic proteins....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
